Vaccine Contract Manufacturing Market

Summary:

The global vaccine contract manufacturing market size reached US$ 2.8 Billion in 2023.
The market is expected to reach US$ 6.1 Billion by 2032, exhibiting a growth rate (CAGR) of 8.8% during 2024-2032.
Based on the region, the market is segregated into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
On the basis of vaccine type, the market is segmented into attenuated, inactivated, subunit-based, toxoid-based, and DNA-based.
Based on the workflow, the market is divided into downstream and upstream.
On the basis of application, the market is classified into human use and veterinary.
The increasing regulatory focus on vaccine quality and safety prompted pharmaceutical companies to seek contract manufacturers with stringent compliance standards and expertise.
The rising trend of personalized medicine for tailored vaccine solutions, encouraging collaborations between biotech firms and contract manufacturers to develop bespoke vaccine products, is aiding the market growth.

Industry Trends and Drivers:

The increasing global demand for vaccines:

The rising prevalence of infectious diseases, coupled with growing awareness about vaccination's role in disease prevention, has led to a higher demand for vaccines worldwide. This demand is further fueled by initiatives from global health organizations, such as the World Health Organization (WHO), that promote immunization as a critical public health strategy. The COVID-19 pandemic has accelerated this trend, highlighting the importance of rapid vaccine development and distribution. As countries strive to immunize their populations against existing and emerging diseases, pharmaceutical companies are increasingly seeking contract manufacturing partners to scale up production, thus strengthening the market growth.

Advancements in vaccine technology:

The development of innovative vaccine platforms, such as mRNA technology, vector-based vaccines, and nanoparticle vaccines, has transformed the vaccine landscape. These technologies allow for faster development timelines and improved efficacy and safety profiles. As pharmaceutical companies adopt these new technologies, the need for specialized manufacturing capabilities becomes crucial. Contract manufacturers that possess expertise in these advanced technologies are in high demand, as they can help bring novel vaccines to market more efficiently. Additionally, ongoing research and development (R&D) efforts aimed at creating vaccines for diseases like human immunodeficiency viruses (HIV), malaria, and influenza are bolstering the market.

Growing emphasis on public health and pandemic preparedness:

Governments and health organizations worldwide are recognizing the necessity of investing in vaccine production capabilities to ensure readiness for potential outbreaks. The COVID-19 pandemic has underscored the vulnerabilities in global health systems and the need for rapid vaccine responses. As a result, many countries are increasing funding for vaccine research and production infrastructure. This emphasis on preparedness encourages collaboration between public health agencies and private companies, leading to more vaccine contracts aimed at establishing reliable supply chains and production capabilities. Furthermore, initiatives like COVAX, which aim to ensure equitable access to vaccines globally as organizations seek partners to fulfil large-scale vaccine production requirements in various regions, is supporting the market growth.

Request for a sample copy of this report: https://www.imarcgroup.com/vaccine-contract-manufacturing-market/requestsample

Vaccine Contract Market Report Segmentation:

Breakup By Vaccine Type:

Attenuated
Inactivated
Subunit-based
Toxoid-based
DNA-based

On the basis of vaccine type, the market is segmented into attenuated, inactivated, subunit-based, toxoid-based, and DNA-based.

Breakup By Workflow:

Downstream
Upstream

Based on the workflow, the market is divided into downstream and upstream.

Breakup By Application:

Human Use
Veterinary

On the basis of application, the market is classified into human use and veterinary.

Breakup By Region:

North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa

Based on the region, the market is segregated into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.

Top Vaccine Contract Market Leaders:

The vaccine contract market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies.

Some of the key players in the market are:

Ajinomoto Co. Inc.
Albany Molecular Research Inc
Catalent Inc
Cobra Biologics Limited (Charles River Laboratories International Inc.)
Cytovance Biologics Inc. (Hepalink USA Inc.)
Fujifilm Holdings Corporation
ICON plc
IDT Biologika GmbH
Lonza Group AG
Merck KGaA
Pharmaceutical Product Development LLC and PRA Health Sciences Inc.

Browse full report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=3872&flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145